BIO’s Comments for USTR Report Highlight Global Threats to Intellectual Property

Why It Matters

Robust IP enforcement is critical to sustaining biotech innovation, attracting capital, and preserving the U.S. bioscience industry’s $3.2 trillion economic impact.

Key Takeaways

• BIO urges USTR to enforce global biotech IP protections.
• Weak IP in Colombia, Russia, Brazil threatens U.S. innovation.
• Trade secret theft by China, Russia highlighted as strategic risk.
• Bioscience sector employs 2.29M, generates $3.2T output.
• Strong patents essential for biotech investment and job creation.

Pulse Analysis

The USTR’s Special 301 Report serves as the United States’ annual barometer of global intellectual‑property environments, shaping diplomatic engagement and trade policy. BIO’s recent comments underscore that biotechnology, a sector driving $3.2 trillion in output and employing over two million Americans, relies on predictable patent regimes to secure the massive R&D investments needed for breakthrough therapies. When foreign jurisdictions fall short—through compulsory licensing, forced technology transfer, or lax enforcement—the cost of innovation rises, eroding the competitive advantage of U.S. firms.

Beyond patent concerns, BIO flags a growing wave of economic espionage targeting trade secrets, with China’s Biosecurity Law and Russia’s recent decrees compelling foreign firms to share proprietary data. Such practices not only undermine commercial confidentiality but also create a chilling effect for small and medium‑sized biotech enterprises that depend on trade‑secret protection to attract venture capital. The organization’s call for coordinated, ally‑based responses reflects a broader consensus that safeguarding intellectual assets is essential for maintaining the pipeline of life‑saving medicines.

For policymakers, BIO’s recommendations translate into actionable steps: embed robust trade‑secret commitments in bilateral and multilateral agreements, enhance information‑sharing mechanisms between government and industry, and prioritize enforcement actions against nations that systematically weaken IP standards. By reinforcing these safeguards, the U.S. can preserve its leadership in biopharmaceutical innovation, sustain high‑value jobs, and ensure that investors continue to fund the next generation of medical breakthroughs.